- Report
- January 2024
- 175 Pages
Global
From €4770EUR$5,000USD£4,061GBP
- Report
- August 2022
- 110 Pages
Global
From €4531EUR$4,750USD£3,858GBP
- Report
- August 2022
- 120 Pages
Global
From €4293EUR$4,500USD£3,655GBP
- Report
- May 2023
- 121 Pages
Global
From €3500EUR$3,930USD£3,084GBP
- Report
- January 2021
- 137 Pages
China, Global
From €3000EUR$3,369USD£2,644GBP
- Report
- May 2024
- 50 Pages
Global
From €2528EUR$2,650USD£2,152GBP
Granisetron is an antiemetic drug used in the treatment of nausea and vomiting caused by chemotherapy and radiotherapy in oncology patients. It is a serotonin 5-HT3 receptor antagonist, which works by blocking the action of serotonin, a natural substance that may cause nausea and vomiting. Granisetron is available in both oral and intravenous formulations, and is often used in combination with other antiemetics. It is generally well tolerated, with few side effects.
Granisetron is used in the treatment of a variety of cancers, including breast, lung, colorectal, and ovarian cancer. It is also used to treat nausea and vomiting associated with other medical conditions, such as HIV/AIDS and postoperative nausea and vomiting.
The Granisetron market is highly competitive, with a number of companies offering products in the space. Some of the major players in the market include GlaxoSmithKline, Merck, Sanofi, Pfizer, and Novartis. Show Less Read more
